PCM
AXSM icon

Peregrine Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Peregrine Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.13M Sell
37,285
-10,011
-21% -$2.17M 0.3% 101
2026
Q1 		$7.99M Buy
47,296
+663
+1% +$115K 0.3% 100
2025
Q4 		$8.52M Sell
46,633
-17,888
-28% -$2.5M 0.26% 109
2025
Q3 		$7.84M Sell
64,521
-8,947
-12% -$1.01M 0.24% 117
2025
Q2 		$7.67M Buy
73,468
+13,747
+23% +$1.46M 0.23% 126
2025
Q1 		$6.97M Sell
59,721
-27,466
-32% -$3.13M 0.23% 123
2024
Q4 		$7.38M Buy
87,187
+15,258
+21% +$1.4M 0.22% 128
2024
Q3 		$6.46M Sell
71,929
-15,444
-18% -$1.35M 0.2% 159
2024
Q2 		$7.03M Buy
87,373
+1,238
+1% +$91.7K 0.21% 169
2024
Q1 		$6.87M Buy
86,135
+1,318
+2% +$111K 0.2% 177
2023
Q4 		$6.75M Sell
84,817
-6,274
-7% -$419K 0.2% 183
2023
Q3 		$6.37M Sell
91,091
-16,442
-15% -$1.23M 0.19% 212
2023
Q2 		$7.73M Sell
107,533
-748
-0.7% -$55.2K 0.21% 198
2023
Q1 		$6.68M Buy
108,281
+11,895
+12% +$781K 0.19% 224
2022
Q4 		$7.43M Sell
96,386
-10,453
-10% -$625K 0.23% 199
2022
Q3 		$4.77M Sell
106,839
-34,445
-24% -$1.72M 0.15% 235
2022
Q2 		$5.41M Sell
141,284
-24,372
-15% -$771K 0.16% 237
2022
Q1 		$6.86M Buy
165,656
+46,358
+39% +$1.44M 0.16% 231
2021
Q4 		$4.51M Buy
119,298
+3,359
+3% +$124K 0.09% 250
2021
Q3 		$3.82M Sell
115,939
-22,996
-17% -$896K 0.08% 252
2021
Q2 		$9.37M Buy
138,935
+10,530
+8% +$632K 0.17% 240
2021
Q1 		$7.27M Sell
128,405
-17,920
-12% -$1.26M 0.13% 251
2020
Q4 		$11.9M Buy
+146,325
New +$10.9M 0.23% 207

Other funds holding AXSM

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return
CA
Cannon Advisors Charlotte, North Carolina $164M AUM 30.34% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return

Peregrine Capital Management's AXSM Position: Q2 2026 in Review

Peregrine Capital Management reduced its Axsome Therapeutics (AXSM) stake by 21% in Q2 2026, selling an estimated $2.17M and leaving 37,285 shares worth $9.13M. The position accounts for 0.3% of the portfolio, ranked #101.

Peregrine Capital Management first reported a position in AXSM in Q4 2020 and has held it in 23 quarters since. The position peaked at $11.9M in Q4 2020. 38 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Peregrine Capital Management held 37,285 shares of Axsome Therapeutics worth $9.13M as of Q2 2026.
  • Peregrine Capital Management sold 10,011 Axsome Therapeutics shares in Q2 2026, an estimated $2.17M.
  • Axsome Therapeutics made up 0.3% of Peregrine Capital Management's portfolio in Q2 2026, its #101 holding.
  • Peregrine Capital Management first reported a position in Axsome Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Peregrine Capital Management's Axsome Therapeutics position peaked at $11.9M in Q4 2020.
  • 38 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Peregrine Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.